Drug intelligence / Profile preview

Hou Gu Mi Xi

Development stage: Unknown
Lead developer: Jiangzhong Pharmaceutical Group
Administration: Oral

Overview

Hou Gu Mi Xi is an orally bioavailable dietary supplement and a formulation derived from the traditional Chinese medicine (TCM) prescription Shen Ling Bai Zhu San. It is designed to address spleen qi deficiency syndrome, a TCM diagnosis characterized by chronic gastrointestinal disorders and systemic symptoms, particularly in patients who have undergone radical gastrectomy for gastric cancer. The product is used as an alternative and complementary intervention to manage chronic postoperative complications such as digestive dysfunction and general weakness associated with spleen qi deficiency. Its mechanism of action is based on traditional herbal principles rather than a defined molecular target[1][2].

Brand names: Hou Gu Mi Xi
Other names: HGMXShen Ling Bai Zhu San-derived formula

Beyond the preview

Go deeper on Hou Gu Mi Xi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hou Gu Mi Xi.

Explore the full profile